Literature DB >> 26801792

Infusional dose-adjusted epoch plus bortezomib for the treatment of plasmablastic lymphoma.

Pasquale L Fedele1,2, Gareth P Gregory3, Michael Gilbertson3, Jake Shortt3,4, Beena Kumar5, Stephen Opat3,4, George Grigoriadis3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26801792     DOI： 10.1007/s00277-016-2601-6

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Factors and Costs Associated With Delay in Treatment Initiation and Prolonged Length of Stay With Inpatient EPOCH Chemotherapy in Patients With Hematologic Malignancies.

Authors:  Melissa K Accordino; Jason D Wright; Sowmya Vasan; Alfred I Neugut; Grace C Hillyer; Dawn L Hershman
Journal:  Cancer Invest       Date:  2017-02-06       Impact factor: 2.176

2.  Durable complete remission with combination chemotherapy and bortezomib in HIV-associated plasmablastic lymphoma.

Authors:  Nivedita Arora; Arjun Gupta; Navid Sadeghi
Journal:  BMJ Case Rep       Date:  2017-10-09

3.  Plasmablastic Lymphoma: Case Report of Prolonged Survival of an Advanced Human Immunodeficiency Patient and Literature Review.

Authors:  Hind Rafei; Ehab El-Bahesh; Antoine Finianos; Min-Ling L Liu; Geraldine P Schechter
Journal:  Case Rep Hematol       Date:  2017-09-24

4.  A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report.

Authors:  Alessandro Broccoli; Laura Nanni; Vittorio Stefoni; Claudio Agostinelli; Lisa Argnani; Michele Cavo; Pier Luigi Zinzani
Journal:  BMC Cancer       Date:  2018-06-08       Impact factor: 4.430

5.  Case Report: Bortezomib Plus CDOP Followed by Sequential Autologous Hematopoietic Stem Cell Transplantation and Lenalidomide-Based Maintenance Therapy in Plasmablastic Lymphoma.

Authors:  Jiao Cai; Ling Qiu; Lei Ma; Nan Zhang; Fang-Yi Fan
Journal:  Front Med (Lausanne)       Date:  2021-12-03

6.  Interleukin-6-dependent growth in a newly established plasmablastic lymphoma cell line and its therapeutic targets.

Authors:  Sohtaro Mine; Tsunekazu Hishima; Akihiko Suganuma; Hitomi Fukumoto; Yuko Sato; Michiyo Kataoka; Tsuyoshi Sekizuka; Makoto Kuroda; Tadaki Suzuki; Hideki Hasegawa; Masashi Fukayama; Harutaka Katano
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

7.  HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases.

Authors:  Ya-Jun Li; Ji-Wei Li; Kai-Lin Chen; Jin Li; Mei-Zuo Zhong; Xian-Ling Liu; Ping-Yong Yi; Hui Zhou
Journal:  Blood Res       Date:  2020-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.